

REMARKS

The applicant wishes again to thank the Examiner for conducting a telephone interview with applicant's representative on June 10, 2009.

During the interview, proposed claim amendments to claims 1 and 15 were discussed. In addition, applicant's representative stated that claims 7, 13 and 14 would be cancelled.

The Examiner indicated that it appeared that the proposed amendments as shown in the claim section of this response would place the application in condition for allowance.

Applicant's representative and the Examiner discussed the possibility of filing a Terminal Disclaimer in regard to U.S. Patent Application 10/585,623. However, as that application is currently pending it was agreed that there was no need to file a Terminal Disclaimer in the present application.

Claims 1 and 15 have been amended to include the isolated human chromosome No. 2 containing fibronectin encoding gene. Claim 1 has been amended to define wherein a higher level of said antibody in said sample compared to a level of said antibody in a control is indicative of immunological recurrent spontaneous abortion. Claim 15 has been amended to define that comparing the determined level with the corresponding level before the treatment; wherein a lower level of said antibody in said sample compared to the level before the treatment is indicative of a positive therapeutic effect of the treatment. Support for the amendment to claim 1 is found on page 13 of the specification and support for the amendment to claim 15 is found on pages 16 and 17 in the specification.

In view of the amendment and cancellation of the claims, it is submitted that the rejection under 112, first and second paragraph are moot.


In view of the cancellation of claims 7, 13 and 14 the rejections under 35 USC 103 are moot.

Applicants preserve all rights to file one or more divisional applications directed to any subject matter disclosed in the application and not presently claimed.

It is submitted that the present application is in condition for allowance and favorable consideration is respectfully requested.

If any questions remain, please contact the undersigned.

Respectfully submitted,



JANET L. CORD

LADAS & PARRY LLP
26 WEST 61ST STREET
NEW YORK, NEW YORK 10023
REG. NO.33778 (212)708-1935